Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CALML3 | P27482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042716 | 0.83 | MAOA (0.45) | MAOAMAOBHTR6CALML3 | |
| SCHEMBL6492267 | 0.83 | MAOA (0.45) | MAOAMAOBHTR6CALML3 | |
| SCHEMBL6212226 | 0.81 | CALML3 (0.56) | MAOAMAOBPRKCIHTR6CALML3 | |
| SCHEMBL6193716 | 0.81 | CALML3 (0.56) | MAOAMAOBPRKCIHTR6CALML3 | |
| SCHEMBL6211752 | 0.81 | F10 (0.49) | MAOAMAOBPRKCICALML3 | |
| SCHEMBL6192212 | 0.81 | F10 (0.49) | MAOAMAOBPRKCICALML3 | |
| SCHEMBL6210178 | 0.80 | MAOA (0.43) | MAOAMAOBHTR6CALML3 | |
| SCHEMBL3041022 | 0.80 | MAOA (0.43) | MAOAHTR6CALML3 | |
| SCHEMBL6241199 | 0.80 | MAOA (0.43) | MAOAHTR6CALML3 | |
| SCHEMBL3039459 | 0.78 | MAOA (0.45) | MAOAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | MAOA 2297/4885MAOB 1604/4885PRKCI 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.